NEW YORK, January 4, 2026, 15:25 ET — Market closed
- TMO ended Friday up 2.25% at $592.51, about 3% below its 52-week high
- Next company catalyst: Q4 and full-year results due before the open on Jan. 29
- Macro in focus before the bell: ISM manufacturing on Jan. 5 and U.S. jobs data on Jan. 9
Thermo Fisher Scientific Inc (NYSE:TMO) shares rose 2.25% to $592.51 on Friday, outpacing a modestly higher U.S. stock market and moving back toward the top of their 52-week range.
That positioning matters going into a new week when investors will be testing whether early-2026 risk appetite holds and how much room the Federal Reserve has to cut rates. Life sciences tools makers like Thermo Fisher tend to trade on expectations for lab and drug-development spending, which can shift quickly when rates and growth expectations move.
Traders will get fresh signals on Monday when the Institute for Supply Management’s manufacturing report is due, followed by the U.S. employment report for December 2025 on Jan. 9, with the Fed’s next policy meeting set for Jan. 27-28.
Technically, the stock has traded between $385.46 and $610.97 over the past 52 weeks, with the high set on Jan. 30 and the low on June 18.
Thermo Fisher’s move on Friday came as other healthcare tools names advanced, including Danaher, while Steris fell.
The company last raised its 2025 revenue and adjusted profit outlook in October after it beat quarterly estimates, pointing to demand for lab tools and benefits from acquisitions. It also flagged ongoing pressure in China tied to a government program for bulk purchases of medical devices at steep discounts.
Deal execution remains a swing factor for 2026. Thermo Fisher agreed in October to buy clinical trial data firm Clario for up to $9.4 billion, including performance-based earn-outs — extra payments tied to how the business performs — and said the deal should close in early 2026 and lift adjusted profit, which strips out certain one-time items. “Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence solutions,” CEO Marc Casper said. Reuters
The next hard catalyst is Jan. 29, when Thermo Fisher will report fourth-quarter and full-year results before the market opens and hold a conference call at 8:30 a.m. ET, the company said.
Income-focused investors also have Jan. 15 on the calendar, when a $0.43-per-share quarterly dividend is due to be paid, the company said.
But the setup cuts both ways: any sign of softer customer orders, slower China trends, or margin pressure from integration and costs could cool the rally after the stock’s climb back near its highs.
U.S. markets reopen Monday, with the January data calendar starting immediately; for Thermo Fisher, the key test is whether management’s Jan. 29 update can validate the stock’s run toward its 52-week high.
